Form 4: Castle Biosciences Director Receives RSU Grant

Director Miles Harrison was granted 11,766 restricted stock units by Castle Biosciences, Inc.

Summary

• Director Miles Harrison received a grant of 11,766 Restricted Stock Units (RSUs) on May 28, 2026.
• Each RSU represents a contingent right to receive one share of Castle Biosciences common stock.
• The grant is subject to a vesting schedule tied to the earlier of the one-year anniversary of the grant or the day before the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon the vesting and settlement of the RSUs.

Risks

• Market volatility affecting the value of equity compensation.
• Potential dilution of existing equity interests.

Future Outlook

The RSUs are scheduled to vest in full on May 28, 2027, or the day preceding the next annual meeting of stockholders, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with shareholder interests.

Comparison to Industry Standards

• The use of RSUs for director compensation is consistent with standard practices for mid-cap biotechnology companies.
• Vesting periods of one year or until the next annual meeting are typical for director equity awards.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future vesting.

Next Steps

• Vesting of the 11,766 RSUs on May 28, 2027, or the day before the next annual meeting.

Key Dates

Keywords

Castle Biosciences, CSTL, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction